Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | THRA | P10827 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | TACR2 | P21452 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SHBG | P04278 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28536768 | 0.92 | ESR1 (0.57) | THRBALDH1A1HSD17B10THRASMN1; SMN2 | |
| SCHEMBL2089568 | 0.92 | ESR1 (0.57) | THRBALDH1A1HSD17B10THRASMN1; SMN2 | |
| SCHEMBL21633839 | 0.92 | ESR1 (0.57) | THRBALDH1A1HSD17B10THRASMN1; SMN2 | |
| SCHEMBL2096437 | 0.86 | THRB (0.53) | THRBCA2ALDH1A1LMNAKMT2A | |
| SCHEMBL145761 | 0.82 | LTA4H (0.52) | THRBCA2CA1ALDH1A1HSD17B10 | |
| SCHEMBL83869 | 0.81 | CA2 (0.65) | THRBCA2CA1ALDH1A1HSD17B10 | |
| SCHEMBL145506 | 0.80 | CALM1 (0.64) | ALDH1A1HPGDSMN1; SMN2LMNAMEN1 | |
| SCHEMBL16933991 | 0.80 | LMNA (0.62) | ALDH1A1SMN1; SMN2LMNACYP3A4KDM4E | |
| SCHEMBL3141911 | 0.79 | ALDH1A1 (0.49) | THRBCA2CA1ALDH1A1HSD17B10 | |
| SCHEMBL7700363 | 0.78 | ALDH1A1 (0.50) | THRBCA2CA1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4707161-A | Lightfastness of dyeings obtained with acid dyes or metal complex dyes on polyamides: treatment with copper hydroxamates | BASF AKTIENGESELLSCHAFT (DE) | 1987-11-17 | — | — | US | claimed |
| CN-111315828-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-09-29 | — | — | CN | disclosed |
| CN-112154167-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-08-22 | — | — | CN | disclosed |
| CN-107918247-B | Colored curable resin composition | 住友化学株式会社 | 2022-03-18 | — | — | CN | disclosed |
| CN-106019840-B | Colored curable resin composition | 东友精细化工有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-112154167-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-12-29 | — | — | CN | disclosed |
| CN-111315828-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-06-19 | — | — | CN | disclosed |
| WO-2020021969-A1 | COMPOSITION, CURED PRODUCT, OPTICAL FILTER, AND PRODUCTION METHOD FOR CURED PRODUCT | 株式会社ADEKA | 2020-01-30 | — | — | WO | disclosed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-4165316-A | Process for preparing sulfinyl chlorides from penicillin sulfoxides | ELI LILLY AND COMPANY (US) | 1979-08-21 | — | — | US | disclosed |
| US-4165315-A | CHLORINATION WITH AN N-CHLORO HALOGENATING AGENT | ELI LILLY AND COMPANY (US) | 1979-08-21 | — | — | US | disclosed |
| US-4115383-A | Alkoxycarbonyl-ethylthio-azetidinones and process for their preparation | ELI LILLY AND COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4081440-A | Sulfinyl halides and their preparation from penicillin sulfoxides | ELI LILLY AND COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
| US-4075203-A | Process for preparing a 3-exomethylenecepham sulfoxide from penicillin sulfoxides | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4048162-A | Process for preparing 3-hydroxy cephalosporins | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4031082-A | Process for preparing 3-acycloxymethyl-2-cephem compounds | ELI LILLY AND COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
| US-4029651-A | ESTERIFICATION | ELI LILLY AND COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
| US-4008231-A | Preparation of 3-methoxymethylcephalosporins | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-4008230-A | Process for preparing 3-hydroxy cephalosporins | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | THRB 2252/4885CA2 3091/4885CA1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.